Since the first clinical use of 131I-labeled prostate-specific membrane antigen (PSMA) ([1][1]), xerostomia has been identified as a relevant side effect of PSMA radioligand therapies (PRLTs) for metastatic castration-resistant prostate cancer. Given the remarkable progress when using 177Lu-labeled
No takes yet. Share an insight, caveat, or question.
Langbein et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: